Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice

Currently, the third generation aromatase inhibitors are the drugs of choice for treatment of early and advanced breast cancer in postmenopausal women. The negative impact of these drugs on bone health is the significant limiting factor during this therapy. Here we report the effect of two aromatase...

Full description

Bibliographic Details
Main Authors:	Abul Kalam, Sushama Talegaonkar, Divya Vohora
Format:	Article
Language:	English
Published:	Elsevier 2017-02-01
Series:	Data in Brief
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352340916307739

id	doaj-6259b3393a074ecc933b9100f0a0e7cd
record_format	Article
spelling	doaj-6259b3393a074ecc933b9100f0a0e7cd2020-11-25T01:32:00ZengElsevierData in Brief2352-34092017-02-0110C44444810.1016/j.dib.2016.12.012Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic miceAbul Kalam0Sushama Talegaonkar1Divya Vohora2Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, IndiaDepartment of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, IndiaDepartment of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, IndiaCurrently, the third generation aromatase inhibitors are the drugs of choice for treatment of early and advanced breast cancer in postmenopausal women. The negative impact of these drugs on bone health is the significant limiting factor during this therapy. Here we report the effect of two aromatase inhibitors viz. letrozole and exemestane alone and in combination with raloxifene on lumbar vertebrae and femoral diaphysis after one month of treatment but no discernible effects were observed on bone when tested by micro CT and strength test except in trabecular number which was reduced in lumbar vertebrae following letrozole and exemestane. Further studies with letrozole and exemestane should be done at higher doses for longer duration of time to check whether effects are observed in other parameters as well. The data is an extension of our published work in Mol. Cell Endocrinology (A. Kalam, S. Talegaonkar, D. Vohora, 2017) [1] describing letrozole-induced bone loss on femoral epiphysis and its reversal by raloxifene.http://www.sciencedirect.com/science/article/pii/S2352340916307739
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Abul Kalam Sushama Talegaonkar Divya Vohora
spellingShingle	Abul Kalam Sushama Talegaonkar Divya Vohora Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice Data in Brief
author_facet	Abul Kalam Sushama Talegaonkar Divya Vohora
author_sort	Abul Kalam
title	Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice
title_short	Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice
title_full	Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice
title_fullStr	Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice
title_full_unstemmed	Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice
title_sort	data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of vcd treated ovotoxic mice
publisher	Elsevier
series	Data in Brief
issn	2352-3409
publishDate	2017-02-01
description	Currently, the third generation aromatase inhibitors are the drugs of choice for treatment of early and advanced breast cancer in postmenopausal women. The negative impact of these drugs on bone health is the significant limiting factor during this therapy. Here we report the effect of two aromatase inhibitors viz. letrozole and exemestane alone and in combination with raloxifene on lumbar vertebrae and femoral diaphysis after one month of treatment but no discernible effects were observed on bone when tested by micro CT and strength test except in trabecular number which was reduced in lumbar vertebrae following letrozole and exemestane. Further studies with letrozole and exemestane should be done at higher doses for longer duration of time to check whether effects are observed in other parameters as well. The data is an extension of our published work in Mol. Cell Endocrinology (A. Kalam, S. Talegaonkar, D. Vohora, 2017) [1] describing letrozole-induced bone loss on femoral epiphysis and its reversal by raloxifene.
url	http://www.sciencedirect.com/science/article/pii/S2352340916307739
work_keys_str_mv	AT abulkalam dataofaromataseinhibitorsaloneandincombinationwithraloxifeneonmicroarchitectureoflumbarvertebraeandstrengthtestinfemoraldiaphysisofvcdtreatedovotoxicmice AT sushamatalegaonkar dataofaromataseinhibitorsaloneandincombinationwithraloxifeneonmicroarchitectureoflumbarvertebraeandstrengthtestinfemoraldiaphysisofvcdtreatedovotoxicmice AT divyavohora dataofaromataseinhibitorsaloneandincombinationwithraloxifeneonmicroarchitectureoflumbarvertebraeandstrengthtestinfemoraldiaphysisofvcdtreatedovotoxicmice
_version_	1725083870819254272

Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice

Similar Items